Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07250763 · ClinicalTrials.gov registry record · Phase 4
Therapeutic Initial Heparin Dosing for Patients With Clots or Certain Heart Conditions Admitted to the Hospital
A Phase 4 study of Atrial Fibrillation and Pulmonary Embolism, sponsored by Inova Health Care Services.
- Active
- Registry status
- Phase 4
- Development phase
- 145
- Enrollment target
- 1
- Study location
NCT07250763 is a Phase 4 study of Atrial Fibrillation and Pulmonary Embolism that is active but no longer recruiting, run by Inova Health Care Services. The registered enrollment target is 145 participants, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07250763, a Phase 4 study of Atrial Fibrillation and Pulmonary Embolism, is active but no longer recruiting, sponsored by Inova Health Care Services.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 145 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial study is to test whether a mathematical calculation, using the patient's gender, weight and kidney function, can better predict a patient's heparin goal dose than a flat number of units per patient weight can. Participants will have the first dose of heparin infusion calculated, after which if adjustments are needed, the Hospital's prebuilt table for results driven dosing for this purpose is used. The researchers will compare the time it takes for the participants to get to the desired goal using the patient's information for calculation versus patients in the past who received the medication using the flat rate. The hypothesis is that the patients with enhanced personal data, gender, weight and kidney function, included for the initial dose, will get to their goal lab value sooner and with less chance of delay or overshooting the goal. A quicker time to goal lab value is beneficial to patients in many ways, including earlier treatment of the clot or coronary issue that the patient is experiencing.
Conditions Studied
Interventions
- DRUG Initial Heparin Dose Modification
Study Locations (1)
Virginia
- Inova Alexandria Hospital - Alexandria
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2023-09-20 |
| Est. Completion | 2027-05-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07250763
The ClinicalTrials.gov registry entry for NCT07250763 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 145 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (95% lower). The listed sponsor is Inova Health Care Services, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention - of which Initial Heparin Dose Modification is the first listed.
NCT07250763 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT07250763 about?
NCT07250763 is a clinical study titled "Therapeutic Initial Heparin Dosing for Patients With Clots or Certain Heart Conditions Admitted to the Hospital". The goal of this clinical trial study is to test whether a mathematical calculation, using the patient's gender, weight and kidney function, can better predict a patient's heparin goal dose than a flat number of units per patient weight can. Participants will have the first dose of heparin infusion ...
What is the current status of trial NCT07250763?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 145 participants. The study started on 2023-09-20. Estimated completion is 2027-05-31.
What conditions does trial NCT07250763 study?
This clinical trial studies the following conditions: Atrial Fibrillation, Pulmonary Embolism, Deep Vein Thrombosis, Acute Cardiac Syndrome, Mechanical Heart Valve Recipients.
What interventions are being tested in trial NCT07250763?
The interventions under investigation include: Initial Heparin Dose Modification (DRUG).
Who is sponsoring clinical trial NCT07250763?
This trial is sponsored by Inova Health Care Services, which has 75 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07250763 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure
RECRUITING · Phase 4
-
Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation
RECRUITING · Phase 4
-
Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress
RECRUITING · Phase 4
-
Ondansetron for the Management of Atrial Fibrillation
RECRUITING · Phase 4
-
EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF)
ACTIVE NOT RECRUITING · Phase 4
-
Targeting Risk Interventions and Metformin for Atrial Fibrillation (TRIM-AF)
ACTIVE NOT RECRUITING · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.